Liora Life Sciences, LLC — SEC Form D Filing
Liora Life Sciences, LLC filed an SEC Form D on October 1, 2026, reporting $300K raised in Other Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 1, 2026
- Amount reported
- $300K
- Round stage
- Pre-seed because the $300,000 raise is characteristic of early-stage capital used to fund initial laboratory validation and proof-of-concept studies.
- Industry
- Other Health Care
- Website
- https://lioralifesciences.com
What the company does
Securities: Equity. Exemption: Rule 506(c). Incorporated: DELAWARE
Problem
Early-stage drug discovery and therapeutic development suffer from high attrition rates and prolonged timelines due to inefficient preclinical screening models.
Solution
Liora Life Sciences develops advanced biological assays and therapeutic platforms to streamline the identification of viable drug candidates.
Why now
The convergence of high-throughput screening technologies and machine learning has created unprecedented opportunities to optimize early-stage therapeutic pipelines.
Source: SEC EDGAR Form D filing